A phase I study of the heparanase inhibitor: PI-88 and weekly docetaxel in patients (PTS) with advanced solid malignancies.

被引：0
|
作者：
Raj, SKS
Basche, M
Gore, L
Grolnic, S
Hunt, J
O'Bryant, CL
Morrow, M
Creese, B
Kangas, M
Sawlwin, D
Eckhardt, SG
Holden, SN
Holden, SN
机构：
[1] Univ Colorado, Ctr Canc, Aurora, CO USA
[2] Progen Ind Ltd, Darra, Australia
[3] Omnicare Clin Res, Sydney, NSW, Australia
来源：
CLINICAL CANCER RESEARCH | 2003年 / 9卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6152S / 6152S
页数：1
相关论文
共 50 条
  • [41] A phase I study of reolysin given intravenously to patients with advanced malignancies.
    Vidal, L.
    Pandha, H.
    Spicer, J.
    Harrington, K. J.
    Allen, S.
    Leader, D.
    Coffey, M.
    Thompson, B.
    Kaye, S.
    De-Bono, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 136S - 136S
  • [42] Phase I and pharmacokinetic study of weekly docetaxel, cisplatin, and daily capecitabine in patients with advanced solid tumors
    Fakih, MG
    Creaven, PJ
    Ramnath, N
    Trump, D
    Javle, M
    Strychor, S
    Repinski, TV
    Zamboni, BA
    Schwarz, JK
    French, RA
    Zamboni, WC
    CLINICAL CANCER RESEARCH, 2005, 11 (16) : 5942 - 5949
  • [43] Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors
    Font, A
    Sanchez, JM
    Rosell, R
    Taron, M
    Martinez, E
    Guillot, M
    Manzano, JL
    Margeli, M
    Barnadas, A
    Abad, A
    LUNG CANCER, 2002, 37 (02) : 213 - 218
  • [44] A Phase l study of BYL719, an α-isoform selective PI3K inhibitor, in Japanese patients with advanced solid malignancies.
    Kogure, Yoshihito
    Yamada, Yasuhide
    Saka, Hideo
    Kitagawa, Chiyoe
    Iwasa, Satoru
    Yamamoto, Noboru
    Aoki, Takuji
    Kakizume, Tomoyuki
    Robson, Matthew
    Quadt, Cornelia
    Mitsuma, Ayako
    Shibata, Takashi
    Ando, Yuichi
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [45] A phase I study of the safety and pharmacodynamic effects of everolimus in combination with lenalidomide in patients with advanced solid malignancies.
    Owonikoko, Taofeek Kunle
    Harvey, R. Donald
    Kauh, John S.
    Lewis, Colleen Margaret
    Hossain, Mohammed S.
    Akintayo, Adebowale O.
    Merriewether, A. Rene
    Chen, Zhengjia
    Hawk, Natalyn Nicole
    Saba, Nabil F.
    Harris, Wayne
    Shin, Dong Moon
    El-Rayes, Bassel F.
    Huang, Chunzi
    Lonial, Sagar
    Lawson, David H.
    Khuri, Fadlo Raja
    Waller, Edmund K.
    Ramalingam, Suresh S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [46] Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
    Hong, David S.
    Schoffski, Patrick
    Calvo, Aitana
    Sarantopoulos, John
    De Olza, Maria Ochoa
    Carvajal, Richard D.
    Prawira, Amy
    Kyi, Chrisann
    Esaki, Taito
    Akerley, Wallace L.
    De Braud, Filippo G.
    Hui, Rina
    Zhang, Tian
    Soo, Ross A.
    Maur, Michela
    Weickhardt, Andrew James
    Chowdhury, Niladri Roy
    Sabatos-Peyton, Catherine
    Kwak, Eunice Lee
    Tan, Daniel Shao-Weng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] A phase I study of BIBF 1120, an orally active triple angiolkinase inhibitor (VEGFR, PDGFR, FGFR) in patients with advanced solid malignancies.
    Lee, CP
    Attard, G
    Poupard, L
    Nathan, PD
    de Bono, JS
    Temple, GMR
    Stefanic, MF
    Padhani, AR
    Judson, IR
    Rustin, GJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 205S - 205S
  • [48] Phase I study of mTORC1/2 inhibitor sapanisertib (TAK-228) in combination with metformin in patients (pts) with mTOR/AKT/PI3K pathway alterations and advanced solid malignancies.
    Coleman, Niamh
    Naing, Aung
    Zhang, Shizhen
    Piha-Paul, Sarina Anne Anne
    Tsimberidou, Apostolia Maria
    Janku, Filip
    Rodon, Jordi
    Pant, Shubham
    Dumbrava, Ecaterina Elena
    Fu, Siqing
    Hong, David S.
    Meric-Bernstam, Funda
    Subbiah, Vivek
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Phase I study of weekly docetaxel and topotecan in the treatment of advanced solid tumors.
    Tan, BR
    Read, W
    Bergeron, K
    Fracasso, PM
    Govindan, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 702S - 702S
  • [50] Phase I study of ATI-1123, a novel human serum albumin-stabilized docetaxel liposomal formulation, in patients with advanced solid malignancies.
    Vemulapalli, S.
    Mita, A. C.
    Gallegos, N. S.
    Anderson, G.
    Charles, J.
    Rogers, J. M.
    Kousba, A.
    Sankhala, K. K.
    Nemunaitis, J. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345